Aperio Group LLC lifted its stake in shares of Zoetis Inc (NYSE:ZTS) by 6.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 309,152 shares of the company’s stock after purchasing an additional 19,282 shares during the period. Aperio Group LLC’s holdings in Zoetis were worth $28,306,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in ZTS. Sun Life Financial INC lifted its position in shares of Zoetis by 604.3% during the second quarter. Sun Life Financial INC now owns 1,310 shares of the company’s stock worth $112,000 after purchasing an additional 1,124 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of Zoetis by 3,033.3% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,410 shares of the company’s stock worth $120,000 after purchasing an additional 1,365 shares in the last quarter. Fort L.P. acquired a new position in shares of Zoetis during the second quarter worth approximately $121,000. Private Capital Group LLC lifted its position in shares of Zoetis by 118.4% during the first quarter. Private Capital Group LLC now owns 1,529 shares of the company’s stock worth $128,000 after purchasing an additional 829 shares in the last quarter. Finally, Lenox Wealth Advisors LLC lifted its position in shares of Zoetis by 259.4% during the second quarter. Lenox Wealth Advisors LLC now owns 1,682 shares of the company’s stock worth $143,000 after purchasing an additional 1,214 shares in the last quarter. Institutional investors own 89.80% of the company’s stock.
In other Zoetis news, insider Catherine A. Knupp sold 46,816 shares of the company’s stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $90.84, for a total value of $4,252,765.44. Following the completion of the sale, the insider now owns 81,640 shares of the company’s stock, valued at $7,416,177.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kristin C. Peck sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $86.22, for a total transaction of $431,100.00. The disclosure for this sale can be found here. Insiders sold 213,467 shares of company stock valued at $19,502,725 in the last ninety days. Insiders own 0.35% of the company’s stock.
Shares of NYSE ZTS opened at $91.47 on Friday. Zoetis Inc has a fifty-two week low of $63.03 and a fifty-two week high of $94.31. The company has a market capitalization of $44.25 billion, a P/E ratio of 38.11, a price-to-earnings-growth ratio of 1.74 and a beta of 1.01. The company has a current ratio of 4.38, a quick ratio of 2.92 and a debt-to-equity ratio of 2.50.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, August 2nd. The company reported $0.77 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.71 by $0.06. Zoetis had a net margin of 19.95% and a return on equity of 72.30%. The business had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.38 billion. During the same period in the prior year, the business posted $0.53 earnings per share. Zoetis’s revenue was up 11.5% compared to the same quarter last year. Research analysts predict that Zoetis Inc will post 3.07 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Tuesday, November 20th will be paid a $0.126 dividend. This represents a $0.50 annualized dividend and a yield of 0.55%. The ex-dividend date of this dividend is Monday, November 19th. Zoetis’s payout ratio is presently 20.83%.
ZTS has been the topic of several analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $105.00 price objective (up from $98.00) on shares of Zoetis in a report on Wednesday. Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Wednesday. Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and set a $95.00 price objective on the stock. in a report on Tuesday, August 21st. They noted that the move was a valuation call. Morgan Stanley increased their price objective on shares of Zoetis from $87.00 to $92.00 and gave the company a “hold” rating in a report on Friday, August 3rd. Finally, Argus increased their price objective on shares of Zoetis from $90.00 to $103.00 and gave the company a “buy” rating in a report on Tuesday, August 14th. Seven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $92.63.
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
See Also: How is the discount rate different from the Federal Funds rate?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.